CCSD Code 0029B: MLH1 promoter hypermethylation test

Key Takeaways

CCSD Code 0029B is a Chapter 34 (pathology) code in the CCSD schedule, used across UK private healthcare to bill MLH1 promoter hypermethylation testing.

The final letter tells you the specimen. CCSD pathology codes map to the NHS National Laboratory Medicine Catalogue (NLMC), and the letter B marks blood, so 0029B is the blood-based version of the test.

MLH1 promoter hypermethylation switches off a DNA mismatch repair gene. In tumor testing a positive result usually signals a sporadic cancer and helps rule Lynch syndrome out, rather than confirm it.

Bupa, AXA Health, and Aviva reimburse CCSD pathology codes, but confirm 0029B and its fee on each provider portal first, and make sure the specimen on the lab report matches the code.

CCSD Code 0029B is a pathology procedure code in the CCSD schedule, used across UK private healthcare to bill for MLH1 promoter hypermethylation testing. It sits in Chapter 34, the pathology chapter, and the final letter, B, shows the test runs on a blood sample.

MLH1 promoter hypermethylation is an epigenetic change that switches off the MLH1 mismatch repair gene. It matters most when a clinician needs to know whether a colorectal or endometrial cancer is sporadic or linked to Lynch syndrome.

This guide covers what the code represents, how CCSD pathology numbering works, which insurers reimburse it, and how to bill it without triggering a rejection.

CCSD Code 0029B: Official description and what it covers

CCSD Code 0029B appears in the CCSD schedule, maintained by the Clinical Coding and Schedule Development (CCSD) Group. The schedule is the reference standard UK private insurers and hospitals use to identify clinical activity.

Code 0029B falls in Chapter 34, the pathology chapter, which is largely mapped to the NHS National Laboratory Medicine Catalogue (NLMC) so private and NHS laboratory tests line up.

Pathology codes are built differently from surgical CCSD codes. A numeric stem identifies the test, and the letter on the end identifies the specimen the test runs on. In 0029B that letter is B, which means blood.

So this is the blood-based MLH1 promoter hypermethylation assay, used to look for a constitutional (germline-level) methylation change, rather than the tissue-based version run on a tumor block.

The table below sets out the key reference data for the code. Confirm the exact official wording and any modifiers against the current CCSD schedule and the CCSD Technical Guide before billing, as pathology entries are reviewed regularly.

What MLH1 promoter hypermethylation shows

MLH1 is one of the DNA mismatch repair (MMR) genes. These genes proofread and correct the small copying errors that happen every time a cell divides. Promoter hypermethylation is a build-up of methyl groups on the MLH1 promoter that switches the gene off without altering the underlying DNA sequence, an effect known as epigenetic silencing.

Once MLH1 is silenced, the cell stops making the MLH1 protein and the mismatch repair system fails. Errors then accumulate in short, repeated stretches of DNA, a state called microsatellite instability (MSI). MSI is the hallmark of mismatch repair deficiency (dMMR), which turns up most often in two cancers:

• Colorectal (bowel) cancer – the most common setting for MMR testing.
• Endometrial (womb) cancer – the other cancer most closely linked to Lynch syndrome.

A laboratory typically assesses methylation by converting the DNA with bisulfite and running a PCR-based assay, such as methylation-specific PCR or pyrosequencing. The result is reported as methylation present or absent, which is what feeds into the interpretation below.

MLH1 promoter hypermethylation, Lynch syndrome and sporadic cancer

This is the part that is easy to get backwards. A positive MLH1 promoter hypermethylation result usually points away from Lynch syndrome, not toward it. Lynch syndrome (also called HNPCC) is caused by an inherited mutation in an MMR gene, while most MMR-deficient tumors are sporadic and driven by methylation the tumor picks up on its own.

Methylation testing is triggered when immunohistochemistry (IHC) shows a tumor has lost both MLH1 and its partner protein PMS2. Around 85% of tumors with that IHC pattern carry MLH1 promoter methylation, and most of it is somatic, meaning the cancer is sporadic. The interpretation runs like this:

• Methylation present: he MLH1 loss is almost certainly sporadic, and Lynch syndrome is unlikely.
• Methylation present with a BRAF V600E mutation: a sporadic cancer is close to certain. BRAF V600E is common in sporadic MMR-deficient tumors and virtually never seen in Lynch syndrome.
• Methylation absent (and no BRAF mutation): the cause has not been explained, so the patient is referred for genetic counseling and germline MMR testing to check for Lynch syndrome.

The blood specimen behind code 0029B has a distinct use. A blood-based MLH1 methylation test looks for a constitutional MLH1 epimutation, where the promoter is methylated at a germline level across the body’s normal cells. This is a rare cause of a Lynch-like presentation, so a blood result is read differently from a one-off methylation change inside a tumor.

One caveat keeps the interpretation honest: methylation is not an absolute rule-out. A small number of genuine Lynch syndrome cancers are also hypermethylated. Where family history strongly suggests an inherited cancer syndrome, clinicians may still pursue germline testing despite a positive methylation result.

Which UK insurers accept CCSD Code 0029B?

UK private medical insurance (PMI) providers each maintain their own agreed tariffs and acceptance rules for CCSD codes. Molecular pathology tests such as MLH1 methylation are often requested by a consultant and may need pre-authorisation, so confirm 0029B directly on each insurer’s provider portal before billing.

Submitting a code the insurer has not agreed, or one that needs prior approval, is a common cause of rejection.

Insurer acceptance can change between CCSD Working Group updates, which happen several times a year, so check each provider portal before invoicing a test you haven’t billed recently.

CCSD Code 0029B fee and reimbursement rates

Each insurer sets and updates its own fee for CCSD pathology codes, so rates differ between providers and change over time. Molecular tests often carry higher fees than routine pathology and are more likely to need pre-authorisation. Always verify the current rate on the relevant insurer’s provider portal rather than relying on a previous invoice.

Some insurers vary the rate by the practitioner’s recognition status, the laboratory used, and whether the test was authorised in advance. Billing above the agreed rate without prior agreement usually leaves a shortfall the patient may be asked to cover, which strains both patient trust and your insurer relationship.

How to submit a claim using CCSD Code 0029B

The standard route for UK private healthcare claims is Healthcode, the eBilling clearinghouse most major PMI providers use. For a molecular pathology test, the specimen and the requesting clinician matter as much as the code itself.

1. Confirm authorisation and referral. Obtain the patient’s pre-authorisation number, and check the test was requested by a recognized consultant. Genetic and molecular tests are the ones most likely to need prior approval.
2. Verify the code and the specimen. Check 0029B on the relevant insurer’s portal (for example, Bupa’s code search) and confirm the specimen matches. Because 0029B is a blood code, do not use it for a test run on tumor tissue.
3. Record the test details. Document the requesting clinician, the specimen type and date, the test performed, and the clinical indication. Incomplete records are a frequent audit trigger.
4. Create the invoice. Include CCSD Code 0029B, the insurer’s agreed fee, the authorisation number, the requesting practitioner’s provider number, and your billing details.
5. Submit via Healthcode. Enter the invoice in Healthcode eBilling, attach any supporting documentation, and submit electronically. Healthcode validates the code structure before transmission, catching format errors early.
6. Track and reconcile. Monitor the claim in Healthcode. Turnaround times vary by insurer, so check the relevant provider portal for expected timelines, and any query or rejection reason appears on the dashboard.

For practices handling molecular pathology claims across several insurers, a claims management system that connects to Healthcode reduces manual entry and flags errors before they reach the insurer.

Manage CCSD billing without the manual work

Pabau connects with Healthcode and supports CCSD billing workflows, so your team spends less time on invoice admin and more time on patient care. See how it works in a live demo.

Book a demo

Common billing errors with CCSD Code 0029B

Most rejections and insurer queries are preventable. The errors below account for the majority of CCSD pathology billing failures, and the first one is specific to how pathology codes are built.

• Specimen mismatch. The final letter must match the sample on the laboratory report. Using 0029B (a blood code) when the test was performed on tumor tissue, or vice versa, will not match the request and report, and is a straightforward denial trigger.
• Missing authorisation number. Bupa, AXA Health, and most other PMI providers need the insurer-issued authorisation number on the invoice. Without it, the claim is usually returned unpaid.
• Wrong molecular code. MLH1 methylation sits close to other MMR and molecular pathology codes. Confirm the description against the current CCSD schedule so you are not billing an adjacent test.
• Wrong fee amount. Billing above the insurer’s agreed rate, even slightly, can lead to part-payment or a refund request. Confirm the exact agreed rate per insurer first.
• Duplicate billing. Submitting the same claim twice, manually or through a system error, creates compliance risk and can trigger an audit across your whole claim history.
• Late submission. Submission windows vary by insurer, so check the relevant provider portal and file within the stated window. Claims filed late are often rejected regardless of clinical accuracy.

Tracking these categories per insurer helps billing teams spot patterns and fix the upstream process. Private practice management tools with built-in claim validation can catch several of these before submission reaches Healthcode.

Related CCSD pathology codes and when to use them

MLH1 methylation is rarely billed in isolation. It usually sits within a wider mismatch repair workup, so the codes around it describe the tests that come before and alongside it. Other Chapter 34 entries, such as 0024B, follow the same specimen-letter logic, so check the schedule before assuming an adjacent number applies.

The table shows how to tell the codes around 0029B apart. For the full Bupa code structure, see Pabau’s Bupa CCSD code reference.

When you are unsure which code applies, check the official CCSD schedule or contact the insurer’s provider relations team. Applying a code that does not match the documented specimen and test is a compliance risk.

A neighboring pathology entry, 0022G, is a reminder that the letter suffix carries the meaning, not the numeric stem alone. For how Bupa procedure codes and fees are structured more broadly, see Pabau’s Bupa fee schedule guide.

Managing CCSD Code 0029B billing in practice management software

Manual pathology billing invites avoidable errors. When teams key in codes, specimen letters, fees, and authorisation numbers by hand across several insurers, transcription mistakes are only a matter of time.

Practice management software like Pabau removes that risk by connecting the test request and result to the invoice in one workflow, whether the request originates from a private GP practice or a specialist consultant.

Pabau supports CCSD billing for UK private healthcare practices, including functional medicine clinics ordering molecular and methylation panels alongside routine pathology. The claims management feature lets billing teams set up CCSD codes including 0029B, attach insurer-specific fee schedules, and submit through Healthcode without re-keying data from the record.

For practices that also carry UK data-protection duties over patient and laboratory records, the UK GDPR compliance checklist covers how to store and process that information correctly.

• Code and specimen setup: configure 0029B once with the correct specimen letter, description, and per-insurer fees for Bupa, AXA Health, Aviva, and others.
• Authorisation tracking: log authorisation numbers against the patient record so they auto-populate on the invoice, removing the most common rejection trigger.
• Healthcode integration: submit claims electronically without leaving the platform, with Healthcode validation catching format errors before transmission.
• Claim status tracking: monitor outstanding, paid, and rejected claims in one dashboard instead of logging into several insurer portals.

Conclusion

CCSD Code 0029B covers MLH1 promoter hypermethylation testing on a blood sample, a molecular pathology test that helps clinicians tell a sporadic MMR-deficient cancer from Lynch syndrome. Billing it cleanly comes down to three things: the specimen letter matching the report, a valid authorisation number, and the current agreed fee for each insurer.

Pabau’s claims management software helps UK private practices configure CCSD pathology codes, track authorisations, and submit clean claims through Healthcode. Getting this right protects the revenue a private practice depends on. To see how it handles a molecular pathology billing workflow, book a demo.

Continue your research

Another molecular pathology code? CCSD Code 0022G covers the C-MYC gene test, a close cousin of MLH1 methylation testing with the same molecular-pathology billing rules.

Billing another blood test? CCSD Code 0024B is another blood-specimen pathology code, so the B suffix and submission rules line up with 0029B.

Need the full Bupa code list? The Bupa CCSD code reference covers the Bupa schedule and billing requirements for UK private practice.

Frequently asked questions